# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
TD Cowen analyst Boris Peaker downgrades Macrogenics (NASDAQ:MGNX) from Buy to Hold.
Stifel analyst Stephen Willey downgrades Macrogenics (NASDAQ:MGNX) from Buy to Hold and lowers the price target from $29 to $7.
Macrogenics (NASDAQ:MGNX) reported quarterly losses of $(0.84) per share which missed the analyst consensus estimate of $(0.61)...
TD Cowen analyst Boris Peaker upgrades Macrogenics (NASDAQ:MGNX) from Hold to Buy.
Investment analysts have revised their price targets upwards for six major stocks this week, with one company expected to see a...
Update on MacroGenics Inc's Phase 2 TAMARACK study of vobramitamab duocarmazine (vobra duo) for metastatic castration-resis...